Article
Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Molecular cancer research : MCR - 1 Sept 2023
Hicks Hannah M, Pozdeyev Nikita, Sams Sharon B, Pugazhenthi Umarani, Bales Elise S, Hofmann Marie-Claude, McKenna Logan R, Schweppe Rebecca E
Abstract excerpt
Mutations in BRAF are common in advanced papillary and anaplastic thyroid cancer (PTC and ATC). However, patients with BRAF-mutant PTC currently lack therapies targeting this pathway. Despite the approved combination of BRAF and MEK1/2 inhibition for patients with BRAF-mutant ATC, these patients often progress. Thus, we screened a panel of BRAF-mutant thyroid cancer cell lines to identify new therapeutic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.